{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzloh2\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzloh2\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/9\\\/19\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/9\\\/19\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/9\\\/19\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/9\\\/19\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EThe DECIDE study demonstrates that the humanized monoclonal antibody daclizumab high-yield process is superior to interferon beta-1a on brain magnetic resonance imaging measures of disease activity in patients with relapsing-remitting multiple sclerosis, supporting previous findings of a reduction in the annualized relapse rate.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Edaclizumab high-yield process\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDECIDE\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Erelapsing-remitting multiple sclerosis\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ebrain MRI lesion activity\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einterferon beta-1a\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ET2 hyperintense\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ET1 hypointense\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eneurology clinical trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Edemyelinating diseases\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003EDaclizumab high-yield process (HYP), an investigational humanized monoclonal antibody, binds to CD25, which modulates interleukin-2 receptor signaling [Gold R et al. \u003Cem\u003ELancet\u003C\/em\u003E. 2013], thereby decreasing the number of abnormally activated T cells and pro-inflammatory lymphoid tissue inducer cells, and expanding and activating CD56 bright natural killer cells.\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EJohn Rose, MD, University of Utah, Salt Lake City, Utah, USA, presented results from the DECIDE study [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01064401\u0026amp;atom=%2Fspmdc%2F15%2F9%2F19.atom\u0022\u003ENCT01064401\u003C\/a\u003E], which demonstrated that in patients with relapsing-remitting multiple sclerosis (RRMS), brain magnetic resonance imaging (MRI) lesion activity was lower with subcutaneous daclizumab HYP compared with interferon beta-1a (IFN-\u03b2-1a).\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EThe DECIDE trial was a phase 3, global, randomized, double-blind multicenter study comparing daclizumab HYP with IFN-\u03b2-1a in 1841 patients with RRMS. Patients were randomized to either subcutaneous daclizumab HYP 150 mg every 4 weeks (n\u2005=\u2005919) or intramuscular IFN-\u03b2-1a 30 \u00b5g once weekly for 96 to 144 weeks (n\u2005=\u2005922). The annualized relapse rate, the primary end point of the study, has been shown to be 45% lower in the daclizumab HYP arm compared with the IFN-\u03b2-1a arm (\u003Cem\u003EP\u2005\u003C\/em\u003E\u0026lt;\u2005.0001) [Kappos L et al. AAN 2015 (abstr S4.003)]. Dr Rose focused on the secondary and tertiary end point findings in the DECIDE trial, including the number of new and newly enlarging T2 hyperintense lesions over 96 weeks, the volume of both T1 hypointense lesions and T2 hyperintense lesions, the number of gadolinium-enhancing lesions, and the change in whole brain volume.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EAt baseline, the mean number of T2 hyperintense lesions was 49.2 in patients randomized to receive daclizumab HYP and 51.8 in those randomized to IFN-\u03b2-1a. The mean number of gadolinium-enhancing lesions was 2.0 and 2.3, respectively, and the mean number of T1 hypointense lesions was 31.8 and 33.9, respectively.\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EAt weeks 24 and 96, the mean number of MRI-defined lesions was significantly lower in the daclizumab HYP arm than the IFN-\u03b2-1a arm (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001).\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EMRI data showed that the number of new and newly emerging T2 hyperintense lesions was reduced by 44% at week 24 in patients assigned to daclizumab HYP vs IFN-\u03b2-1a (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001), and by 54% at week 96 (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001). Similarly, the number of new T1 hypointense lesions was reduced by 37% at week 24 and by 52% at week 96 (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001) in the daclizumab HYP arm relative to IFN-\u03b2-1a. Compared with IFN-\u03b2-1a, daclizumab was associated with a 38% reduction (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001) in the number of gadolinium-enhancing lesions at week 24 and a 65% reduction (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001) at week 96.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EThe median reduction percentage from baseline in the volume of T2 hyperintense lesions was significantly greater in the group that received daclizumab HYP compared with those treated with IFN-\u03b2-1a at week 24 (\u003Cem\u003EP\u2005\u003C\/em\u003E=\u2005.0188). However, although the median volume percentage of T2 hyperintense lesions was greater at week 96 than at baseline in both groups, this increase was significantly lower with daclizumab HYP compared with IFN-\u03b2-1a (\u003Cem\u003EP\u2005\u003C\/em\u003E\u0026lt;\u2005.0001). Additionally, the median percentage increase from baseline in volume of T1 hypointense lesions was significantly lower in the daclizumab HYP arm vs IFN-\u03b2-1a arm at both weeks 24 and 96 (\u003Cem\u003EP\u2005\u003C\/em\u003E=\u2005.0003 and \u003Cem\u003EP\u2005\u003C\/em\u003E\u0026lt;\u2005.0001, respectively). Finally, daclizumab HYP was associated with significantly less brain volume loss from baseline to week 24 (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.03) and week 24 to week 96 (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.0001) compared with IFN-\u03b2-1a.\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EDr Rose concluded that daclizumab HYP has the potential to offer a more effective treatment for RRMS than IFN-\u03b2-1a with a positive benefit\/risk profile.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/9\/19.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzloh2\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}